Treatment Clinical Trials for Prostate Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for prostate cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 222
1 2 3 ... 9 Next >

  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1173 locations

  • Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer

    This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
    Location: 404 locations

  • Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery

    This randomized phase II / III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.
    Location: 136 locations

  • Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

    This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of cancer in the body while minimizing radiation exposure of surrounding normal tissue.
    Location: 70 locations

  • Radiation Therapy and Cisplatin or Mitomycin and Fluorouracil in Treating Patients with Non-Muscle Invasive Stage I Bladder Cancer

    This phase II trial studies how well radiation therapy when given together with cisplatin or mitomycin and fluorouracil prevents cancer from returning after surgery in patients with bladder cancer that has not invaded the bladder muscle but has not responded to standard treatment. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, mitomycin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving these chemotherapy drugs may make tumor cells more sensitive to radiation therapy.
    Location: 69 locations

  • Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

    The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and / or abiraterone.
    Location: 18 locations

  • Phase 1 / 1b Study of MGCD516 in Patients With Advanced Cancer

    MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT / PDGFRA / KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.
    Location: 16 locations

  • Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer

    This randomized phase III trial studies intensity-modulated radiation therapy (IMRT) or proton beam therapy (proton beam radiation therapy) (PBT) in treating patients with prostate cancer. Radiation therapy uses high energy x-rays or protons to kill tumor cells and shrink tumors. It is not yet known whether IMRT or PBT is more effective in treating patients with prostate cancer.
    Location: 15 locations

  • Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

    The purpose of this study is to determine whether DCVAC / PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.
    Location: 13 locations

  • ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

    The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
    Location: 12 locations

  • Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

    The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
    Location: 12 locations

  • Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

    This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric / GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric / gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
    Location: 11 locations

  • Olaparib with or without Cediranib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Olaparib and cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 10 locations

  • Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer

    This randomized pilot clinical trial studies the best way to give abiraterone acetate in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgen made by the body.
    Location: 10 locations

  • Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

    The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.
    Location: 9 locations

  • Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

    This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway inhibitor. This adaptive design study includes a cohort phase and a potential randomization phase. An initial concurrent dosing evaluation will evaluate the safety and tolerability of a treatment regimen that employs a concurrent start time for atezolizumab and radium-223 dichloride (Cohort 1). If concurrent dosing is found to be safe and tolerable in Cohort 1, additional participants will be enrolled and eligible participants will be randomized in a 1:1:1 ratio to Arms A, B, and C. If concurrent dosing is not tolerated in Cohort 1, new participants will be enrolled in a staggered dosing evaluation: Cohort 2 (28-day radium-223 dichloride run-in, atezolizumab will begin on Day 1 of Cycle 2) and Cohort 3 (56-day radium-223 dichloride run-in, atezolizumab will begin on Day 1 of Cycle 3). If the Cohort 2 schedule is tolerable, then additional participants will be enrolled using this treatment schedule; If the Cohort 2 schedule is not tolerable, subsequent participants will be enrolled in Cohort 3. If the Cohort 3 schedule is tolerable, then additional participants will be enrolled using this treatment schedule. If Cohort 3 schedule is not tolerable, no additional participant will be enrolled in the study.
    Location: 9 locations

  • Apalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate, and Stereotactic, Ultra-hypofractionated Radiation Therapy in Treating Patients with Very High Risk Prostate Cancer

    This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy work in treating patients with very high risk prostate cancer. Hormone therapy using apalutamide, abiraterone acetate, prednisone, and leuprolide acetate may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells. Stereotactic, ultra-hypofractionated radiation therapy is a type of radiation therapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving apalutamide, abiraterone acetate, prednisone, and leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy may work better in treating patients with prostate cancer.
    Location: 8 locations

  • Phase I / II Study of IMMU-132 in Patients With Epithelial Cancers

    The primary objective is to evaluate the safety and tolerability of IMMU-132 as a single agent administered in 3-week treatment cycles for up to 8 cycles, in previously treated patients with advanced epithelial cancer.The secondary objectives are to obtain initial data concerning pharmacokinetics, immunogenicity, and efficacy with this dosing regimen. IMMU-132 targets the TROP-2 antigen which is expressed on a variety of cancers. The antibody, RS7, is attached to SN38, which is the active metabolite of irinotecan. This is planned as a multi-center study. In Phase II, up to 130 patients (assessable) in triple-negative breast cancer, up to 100 patients (assessable) in non-small cell and small-cell lung cancer and up to 50 patients (assessable) per other cancer types included in the protocol will be studied at the 10 mg / kg dose.
    Location: 8 locations

  • Ultra-hypofractionated Stereotactic Body Radiation Therapy with or without Short Course Degarelix in Treating Patients with Intermediate-Risk Prostate Cancer

    This randomized phase III trial studies how well ultra-hypofractionated stereotactic body radiation therapy alone works compared to ultra-hypofractionated stereotactic body radiation therapy and short course degarelix in treating patients with intermediate-risk prostate cancer. Ultra-hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using degarelix may fight prostate cancer by lowering the amount of testosterone the body makes. Giving ultra-hypofractionated stereotactic body radiation therapy and a short course of degarelix may work better in treating patients with prostate cancer.
    Location: 6 locations

  • A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

    This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide alone in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone) and failure of, ineligibility for, or refusal of a taxane regimen. Participants will be randomized to one of the two treatment arms (atezolizumab in combination with enzalutamide, and enzalutamide alone) in a 1:1 ratio (experimental to control arm) in global randomized phase. Participants will receive treatment until investigator-assessed confirmed radiographic disease progression per Prostate Cancer Working Group 3 (PCWG3) criteria or unacceptable toxicity.
    Location: 8 locations

  • A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

    The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
    Location: 7 locations

  • A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

    The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
    Location: 6 locations

  • Dose-escalation Study of BAY1129980

    The purpose of this study is to evaluate: - The side effects of BAY1129980 when given every 21 days different dose levels. - Determine the dose level of BAY1129980 that should be tested in future clinical research studies. - Measure how much BAY1129980 is in the blood at specific times after administration. - If treatment with BAY1129980 shows any effect on reducing the tumor growth. - If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not. - If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).
    Location: 7 locations

  • LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer

    This randomized phase II trial studies how well enzalutamide with standard luteinizing hormone-releasing hormone (LHRH) analogue therapy work compared to the standard therapy of LHRH analogue and bicalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic). Androgens are male sex hormones that can cause the growth of prostate cancer cells. Anti-hormone therapy, such as enzalutamide and bicalutamide, block the effect of androgens in prostate tumor cells. LHRH analogue therapy stops the body from making the male sex hormone testosterone. It is not yet known whether enzalutamide with LHRH analogue therapy is more effective than bicalutamide with LHRH analogue therapy in treating patients with metastatic prostate cancer.
    Location: 6 locations

  • A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

    The purpose of this study is to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study will also evaluate the safety of enzalutamide plus ADT in mHSPC.
    Location: 7 locations


1 2 3 ... 9 Next >